logo

For the Inventor, By the Inventor

Tilburg, Netherlands

Marc René De Jonge

This inventor holds 24 USPTO granted patents and 2 published patent applications and 8 EPO patents, primarily in HIV Inhibition. Top assignees: Janssen Pharmaceutica Nv, Janssen Pharmaceutica, Tibotec Bvba. Active years: 2005-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc René De Jonge. Retrieved from https://idiyas.com/inventor/marc-rené-de-jonge

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 

% Patents Active = 58.3


Average Co-Inventor Count = 10.5

ph-index = 8

Forward Citations = 300(Granted Patents)


Location History:

  • 5045 CA Tilburg, NL (2005)
  • 2340 Beerse, BE (2007)
  • CA Tilburg, NL (2006 - 2009)
  • Hontenissestraat, NL (2011 - 2013)
  • Tilburg, NL (2006 - 2014)
  • Leidschendam, NL (2017 - 2020)

Company Filing History:

goldMedal19 out of 2,101 
 
Janssen Pharmaceutica Nv
 patents
silverMedal1 out of 32 
 
Janssen Pharmaceutica
 patents
bronzeMedal1 out of 13 
 
Tibotec Bvba
 patents
4. 1 out of 67 
 
Tibotec Pharmaceuticals Ltd.
 patents
5. 2 out of 834,570 
Other
 patents

Years Active: 2005-2020

Loading Chart...
Loading Chart...
Areas of Expertise:
HIV Replication
Pyrimidines
Purine Derivatives
Triazines
GSK3 Inhibitors
Prodrugs
Bacterial ATP Synthase
Heteroaryl Amines
Amide Derivatives
Pyrazinone Derivatives
2,4-Disubstituted Triazines
24 patents (USPTO):Explore Patents
1. 10611732 - HIV replication inhibiting pyrimidines (2020-04-07),
2. 10370340 - HIV replication inhibiting pyrimidines (2019-08-06),
3. 9981919 - HIV replication inhibiting pyrimidines (2018-05-29),
4. 9580392 - HIV replication inhibiting pyrimidines (2017-02-28),
5. 8828982 - Pyrimidine derivatives for the prevention of HIV infection (2014-09-09),
6. 8530655 - HIV replication inhibiting pyrimidines (2013-09-10),
7. 8088891 - Bacterial ATP synthase binding domain (2012-01-03),
8. 8080551 - HIV inhibiting pyrimidines derivatives (2011-12-20),
9. 8026248 - HIV inhibiting pyrimidine derivatives (2011-09-27),
10. 8026245 - HIV replication inhibiting purine derivatives (2011-09-27),
11. 8003789 - HIV replication inhibiting pyrimidines (2011-08-23),
12. 7923554 - HIV inhibiting 1,2,4-triazin-6-one derivatives (2011-04-12),
13. 7763631 - Prodrugs of HIV replication inhibiting pyrimidines (2010-07-27),
14. 7585870 - HIV replication inhibiting pyrimidines and triazines (2009-09-08),
15. 7585861 - HIV inhibiting 1,2,4-triazines (2009-09-08),

Title: Marc René de Jonge - Innovative Inventor from Tilburg

Introduction: Marc René de Jonge is a renowned inventor hailing from Tilburg, Netherlands, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Marc René de Jonge holds several patents in the areas of sustainable energy solutions, advanced robotics, and smart home technologies, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Marc René de Jonge has established himself as a pioneer in the world of inventions. His work has been recognized globally for its impact on improving efficiency and sustainability across industries.

Collaborations: Throughout his career, Marc René de Jonge has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work in multidisciplinary teams has led to the development of cutting-edge technologies.

Conclusion: Marc René de Jonge's passion for innovation and dedication to creating solutions for the future continue to inspire the next generation of inventors. His legacy as a visionary inventor from Tilburg, NL, is sure to endure for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…